KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Assets (2016 - 2025)

Historic Assets for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to $5.0 billion.

  • Alnylam Pharmaceuticals' Assets rose 1713.09% to $5.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $5.0 billion, marking a year-over-year increase of 1713.09%. This contributed to the annual value of $5.0 billion for FY2025, which is 1713.09% up from last year.
  • Alnylam Pharmaceuticals' Assets amounted to $5.0 billion in Q4 2025, which was up 1713.09% from $4.9 billion recorded in Q3 2025.
  • Alnylam Pharmaceuticals' Assets' 5-year high stood at $5.0 billion during Q4 2025, with a 5-year trough of $3.3 billion in Q1 2021.
  • Its 5-year average for Assets is $3.9 billion, with a median of $3.7 billion in 2021.
  • In the last 5 years, Alnylam Pharmaceuticals' Assets soared by 4279.85% in 2021 and then crashed by 510.09% in 2022.
  • Alnylam Pharmaceuticals' Assets (Quarter) stood at $3.6 billion in 2021, then dropped by 2.66% to $3.5 billion in 2022, then grew by 7.99% to $3.8 billion in 2023, then rose by 10.71% to $4.2 billion in 2024, then increased by 17.13% to $5.0 billion in 2025.
  • Its Assets stands at $5.0 billion for Q4 2025, versus $4.9 billion for Q3 2025 and $4.6 billion for Q2 2025.